{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:39:48Z","timestamp":1793227188611,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014935","name":"BioCryst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.anai.2025.07.012","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T09:09:00Z","timestamp":1753434540000},"page":"681-688.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oral berotralstat for hereditary angioedema prophylaxis in patients aged 2 to &lt;12 years"],"prefix":"10.1016","volume":"135","author":[{"given":"Jolanta","family":"Bernatoniene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lisande","family":"Bourgoin-Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Cancian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pagnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Stobiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Kinaciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Phillips-Angles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Gayet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi-Anna","family":"Bara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mateescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"DeSpirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Iocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Ayg\u00f6ren-P\u00fcrs\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.anai.2025.07.012_bib0001","doi-asserted-by":"crossref","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","article-title":"Hereditary angioedema: epidemiology and burden of disease","volume":"41","author":"Lumry","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"2","key":"10.1016\/j.anai.2025.07.012_bib0002","first-page":"82","article-title":"Pathophysiology and underlying mechanisms in hereditary angioedema","volume":"38","author":"L\u00f3pez Lera","year":"2021","journal-title":"Balk Med J"},{"issue":"7","key":"10.1016\/j.anai.2025.07.012_bib0003","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.anai.2025.07.012_bib0004","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1177\/00099228231155703","article-title":"A comprehensive management approach in pediatric and adolescent patients with hereditary angioedema","volume":"62","author":"Tachdjian","year":"2023","journal-title":"Clin Pediatr (Phila)"},{"issue":"5","key":"10.1016\/j.anai.2025.07.012_bib0005","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/pai.13065","article-title":"Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children","volume":"30","author":"Reshef","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.07.012_bib0006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12016-021-08832-x","article-title":"Current and prospective targets of pharmacologic treatment of hereditary angioedema types 1 and 2","volume":"61","author":"Fijen","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.07.012_bib0007","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1710-1492-9-29","article-title":"Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe","volume":"9","author":"Zanichelli","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.07.012_bib0008","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/PEC.0000000000002402","article-title":"Recognition, evaluation, and management of pediatric hereditary angioedema","volume":"37","author":"Krack","year":"2021","journal-title":"Pediatr Emerg Care"},{"issue":"20","key":"10.1016\/j.anai.2025.07.012_bib0009","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/archinte.161.20.2417","article-title":"Hereditary angioedema: a broad review for clinicians","volume":"161","author":"Nzeako","year":"2001","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.anai.2025.07.012_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100792","article-title":"The multifactorial impact of receiving a hereditary angioedema diagnosis","volume":"16","author":"Raasch","year":"2023","journal-title":"World Allergy Organ J"},{"issue":"suppl 1","key":"10.1016\/j.anai.2025.07.012_bib0011","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.2500\/aap.2020.41.200042","article-title":"Hereditary angioedema: special considerations in children","volume":"41","author":"Johnston","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"12","key":"10.1016\/j.anai.2025.07.012_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/pai.14268","article-title":"Hereditary angioedema in children: review and practical perspective for clinical management","volume":"35","author":"Pagnier","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.anai.2025.07.012_bib0013","unstructured":"CINRYZE prescribing information. Takeda Pharmaeuticals U.S.A. 2024. Accessed August 7, 2025. Available at: https:\/\/www.fda.gov\/media\/75907\/download."},{"key":"10.1016\/j.anai.2025.07.012_bib0014","unstructured":"CINRYZE summary of product characteristics. Takeda Manufacturing Austria Agric. 2025. Accessed August 7, 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cinryze-epar-product-information_en.pdf."},{"key":"10.1016\/j.anai.2025.07.012_bib0015","unstructured":"HAEGARDA Prescribing Information. CSL Behring; 2020. Accessed August 7, 2025. Available at: https:\/\/labeling.cslbehring.com\/PI\/US\/HAEGARDA\/EN\/HAEGARDA-Prescribing-Information.pdf."},{"key":"10.1016\/j.anai.2025.07.012_bib0016","unstructured":"List of Nationally Authorised Medicinal Products. Active Substance: Human Plasma Protease C1 Inhibitor. European Medicines Agency; 2024. Accessed August 7, 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/human-plasma-protease-c1-inhibitor-nationally-authorised-products-list-nationally-authorised-medicinal-products-psusa00010163201608_en.pdf."},{"key":"10.1016\/j.anai.2025.07.012_bib0017","unstructured":"TAKHZYRO prescribing information. Takeda Pharmaeuticals U.S.A. 2025. Accessed August 7, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761090s003lbl.pdf."},{"key":"10.1016\/j.anai.2025.07.012_bib0018","unstructured":"TAKHZYRO Summary of Product Characteristics. Takeda Pharmaceuticals International; 2025. Accessed August 7, 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/takhzyro-epar-product-information_en.pdf."},{"issue":"3","key":"10.1016\/j.anai.2025.07.012_bib0019","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaip.2023.12.019","article-title":"Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: the open-label extension of the apex-2 randomized trial","volume":"12","author":"Kiani-Alikhan","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2025.07.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2024.100882","article-title":"Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial","volume":"17","author":"Honda","year":"2024","journal-title":"World Allergy Organ J"},{"issue":"6","key":"10.1016\/j.anai.2025.07.012_bib0021","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/all.14670","article-title":"Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial","volume":"76","author":"Ohsawa","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2025.07.012_bib0022","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.07.012_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12035","article-title":"Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study","volume":"11","author":"Farkas","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.anai.2025.07.012_bib0024","unstructured":"National Institutes of Health. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Accessed August 7, 2025. Available at: https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf."},{"issue":"1","key":"10.1016\/j.anai.2025.07.012_bib0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaip.2023.09.009","article-title":"Lanadelumab in patients 2 to less than 12 years old with hereditary angioedema: results from the phase 3 SPRING study","volume":"12","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"suppl 24","key":"10.1016\/j.anai.2025.07.012_bib0026","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/pai.13170","article-title":"Pediatric angioedema: essential features and preliminary results from the Hereditary Angioedema Global Registry in Italy","volume":"31","author":"Cancian","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.07.012_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/pai.70072","article-title":"Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER\/ENABLE","volume":"36","author":"Tachdjian","year":"2025","journal-title":"Pediatr Allergy Immunol"},{"issue":"10","key":"10.1016\/j.anai.2025.07.012_bib0028","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0009922815616886","article-title":"Pediatric hereditary angioedema: onset, diagnostic delay, and disease severity","volume":"55","author":"Christiansen","year":"2016","journal-title":"Clin Pediatr (Phila)"},{"issue":"1","key":"10.1016\/j.anai.2025.07.012_bib0029","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/21556660.2020.1863699","article-title":"Hereditary angioedema patients would prefer newer-generation oral prophylaxis","volume":"10","author":"Geba","year":"2021","journal-title":"J Drug Assess"},{"issue":"2","key":"10.1016\/j.anai.2025.07.012_bib0030","doi-asserted-by":"crossref","first-page":"AB136","DOI":"10.1016\/j.jaci.2022.12.425","article-title":"Disease and treatment burden of hereditary angioedema (HAE) in pediatric patients: assessment by caregivers","volume":"151","author":"Tachdjian","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:18:27Z","timestamp":1772882307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625003527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1081120625003527"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.07.012","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral berotralstat for hereditary angioedema prophylaxis in patients aged 2 to <12 years","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}